Bayer to develop and market Cytokinetics’ aficamten in Japan
Bayer will obtain rights to Cytokinetics’ aficamten in Japan, in exchange for around €70m in upfront and near-term payments, up to €490m in commercial milestone payments, along with tiered royalties on future sales
